Frova

Frova is a brand name of frovatriptan, approved by the FDA in the following formulation(s):

FROVA (frovatriptan succinate - tablet; oral)

• 
  Manufacturer: ENDO PHARMS
  
  Approval date: November 8, 2001
  
  Strength(s): EQ 2.5MG BASE ^[RLD]

Has a generic version of Frova been approved?

No. There is currently no therapeutically equivalent version of Frova available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Frova. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Use of tetrahydrocarbazone derivatives as 5HT.sub.1 receptor agonists
  Patent 5,464,864
  Issued: November 7, 1995
  Inventor(s): King; Francis D. & Gaster; Laramie M. & Kaumann; Alberto J. & Young; Rodney C.
  Assignee(s): SmithKline Beecham P.L.C.
  ##STR1## Use of a compound of general formula (I), wherein R.sup.1 represents hydrogen, halogen, trifluoromethyl, nitro, hydroxy, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, arylC.sub.1-6 alkoxy, --CO.sub.2 R.sup.4, --(CH.sub.2).sub.n CN, --(CH.sub.2).sub.n CONR.sup.5 R.sup.6, --(CH.sub.2).sub.n SO.sub.2 NR.sup.5 R.sup.6, C.sub.1-6 alkanoylamino(CH.sub.2).sub.n, or C.sub.1-6 alkylsulphonylamino(CH.sub.2).sub.n ; R.sup.4 represents hydrogen, C.sub.1-6 alkyl or arylC.sub.1-6 alkyl; R.sup.5 and R.sup.6 each independently represent hydrogen or C.sub.1-6 alkyl, or R.sup.5 and R.sup.6 together with the nitrogen atom to which they are attached form a ring; n represents 0, 1 or 2; and R.sup.2 and R.sup.3 each independently represent hydrogen, C.sub.1-6 alkyl; or benzyl or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino or hexahydroazepino ring; or a physiologically acceptable salt thereof, in the manufacture of a medicament for the treatment of a condition where a 5-HT.sub.1 -like agonist is indicated, for example migraine. Novel compounds of formula (I), processes for preparing them and pharmaceutical compositions containing them are also described.
  
  Patent expiration dates:
  
  
  • November 7, 2015
    
    ✓ 
    Patent use: ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
  
  



• 
  Enantiomers of carbazole derivatives as 5-HT.sub.1 -like agonists
  Patent 5,616,603
  Issued: April 1, 1997
  Inventor(s): Borrett; Gary T. & Kitteringham; John & Porter; Roderick A. & Shipton; Mark R. & Vimal; Mythily & Young; Rodney C.
  Assignee(s): SmithKline Beecham plc
  A (+)or (-) enantiomer of a compound of formula (I) wherein R.sup.4 is methyl or ethyl, or a salt, solvate or hydrate thereof, processes for preparing said compounds and pharmaceutical compositions containing them. Compounds of formula (+) are 5-HT.sub.1 -like agonists.
  
  Patent expiration dates:
  
  
  • April 1, 2014
    
    ✓ 
    Patent use: ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
  
  



• 
  Medicaments
  Patent 5,637,611
  Issued: June 10, 1997
  Inventor(s): King; Francis D. & Gaster; Laramie M. & Kaumann; Alberto J. & Young; Rodney C.
  Assignee(s): SmithKline Beecham p.l.c.
  Use of a compound of general formula (I): ##STR1## wherein: R.sup.1 represents hydrogen, halogen, trifluoromethyl, nitro, hydroxy, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, arylC.sub.1-6 alkoxy, --CO.sub.2 R.sup.4, --(CH.sub.2).sub.n CN, --(CH.sub.2).sub.n CONR.sup.5 R.sup.6, --(CH.sub.2).sub.n SO.sub.2 NR.sup.5 R.sup.6, C.sub.1-6 alkanoylamino (CH.sub.2).sub.n, or C.sub.1-6 alkylsulphonylamino (CH.sub.2).sub.n ; R.sup.4 represents hydrogen, C.sub.1-6 alkyl or arylC.sub.1-6 alkyl; R.sup.5 and R.sup.6 each independently represent hydrogen or C.sub.1-6 alkyl, or R.sup.5 and R.sup.6 together with the nitrogen atom to which they are attached form a ring; n represents 0, 1 or 2; and R.sup.2 and R.sup.3 each independently represent hydrogen, C.sub.1-6 alkyl or benzyl or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino or hexahydroazepino ring; or a physiologically acceptable salt thereof, in the manufacture of a medicament for the treatment of a condition where a 5-HT.sub.1 -like agonist is indicated, for example migraine. Novel compounds of formula (I), processes for preparing them and pharmaceutical compositions containing them are also described.
  
  Patent expiration dates:
  
  
  • June 10, 2014
    
    ✓ 
    Patent use: ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
  
  



• 
  Medicaments 1,2,3,4-tetrahydrocarbazoles and 5-HT.sub.1 agonist use thereof
  Patent 5,827,871
  Issued: October 27, 1998
  Inventor(s): King; Francis David & Gaster; Laramie Mary & Kaumann; Alberto Julio & Young; Rodney Christopher
  Assignee(s): Smithkline Beecham plc
  Use of a compound of general formula (I): ##STR1## wherein R.sup.1 represents hydrogen, halogen, trifluoromethyl, nitro, hydroxy, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, arylC.sub.1-6 alkoxy, --CO.sub.2 R.sup.4, --(CH.sub.2).sub.n CN, --(CH.sub.2).sub.n CONR.sup.5 R.sup.6, --(CH.sub.2).sub.n SO.sub.2 NR.sup.5 R.sup.6, C.sub.1-6 alkanoylamino(CH.sub.2).sub.n, or C.sub.1-6 alkylsulphonylamino(CH.sub.2).sub.n ; R.sup.4 represents hydrogen, C.sub.1-6 alkyl or arylC.sub.1-6 alkyl; R.sup.5 and R.sup.6 each independently represent hydrogen or C.sub.1-6 alkyl, or R.sup.5 and R.sup.6 together with the nitrogen atom to which they are attached form a ring; n represents 0, 1 or 2; and R.sup.2 and R.sup.3 each independently represent hydrogen, C.sub.1-6 alkyl or benzyl or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino or hexahydroazepino ring; or a physiologically acceptable salt thereof, in the manufacture of a medicament for the treatment of a condition where a 5-HT.sub.1 -like agonist is indicated, for example migraine. Novel compounds of formula (I), processes for preparing them and pharmaceutical compositions containing them are also described.
  
  Patent expiration dates:
  
  
  • October 27, 2015
    
    ✓ 
    Patent use: ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
  
  



• 
  Enantiomer of carbazole derivative as 5-HT1-like agonists
  Patent 5,962,501
  Issued: October 5, 1999
  Inventor(s): Borrett; Gary Thomas & Kitteringham; John & Porter; Roderick Alan & Shipton; Mark Ralph & Vimal; Mythily & Young; Rodney Christopher
  Assignee(s): SmithKline Beecham, p.l.c.
  A (+) or (-) enantiomer of a compound of formula (I) wherein R.sup.4 is methyl or ethyl, or a salt, solvate, or hydtrate thereof, processes for preparing said compounds and pharmaceutical compostions containing them. Compounds of formula (+) are 5-HT.sub.1 -like agonists.
  
  Patent expiration dates:
  
  
  • December 16, 2013
    
    ✓ 
    Patent use: ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
  
  

See also...

• Frova Consumer Information (Wolters Kluwer)
• Frova Consumer Information (Cerner Multum)
• Frova Advanced Consumer Information (Micromedex)
• Frova AHFS DI Monographs (ASHP)
• Frovatriptan Consumer Information (Wolters Kluwer)
• Frovatriptan Consumer Information (Cerner Multum)
• Frovatriptan Advanced Consumer Information (Micromedex)
• Frovatriptan Succinate AHFS DI Monographs (ASHP)